Company: HURA
Filing Date: 2025-08-12
Form Type: S-1
Source: 0001193125-25-179009
Chunk: 161

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-08-12
Form: S-1
Chunk 161
---
 pursuant to the terms and conditions of the TuHURA-Kineta Merger Agreement, each share of Kineta common stock, par value $0.001 per share (each, a “Share”), issued and 101

outstanding immediately prior to the First Merger, was converted into the right to receive 0.185298 shares of our common stock, par value $0.001 per share, for an aggregate of approximately 2,868,169 shares of our common stock. Also pursuant to the terms and conditions of the TuHURA-Kineta Merger Agreement, each Share is also entitled to (i) its pro rata portion of approximately 1,129,885 shares of our common stock to be issued after six months following the closing of the Kineta Merger, subject to adjustment for losses incurred or accrued during the six month period from the closing of the Kineta Merger, and (ii) the right to its pro rata share of cash consideration received by Kineta pursuant to disposed asset payments related to legacy Kineta assets. Such payments, if any, will be made at a later date and in accordance with the terms of the TuHURA-Kineta Merger Agreement. In each case, in lieu of the issuance of any fractional shares of our common stock, we will pay an amount equal to the product of (A) such fractional share and (B) $5.7528. Components of Results of Operations Revenue We did not generate any revenue and does not expect to generate any revenue from the sale of products in the near future. Research and Development Expenses To date, our research and development expenses have related primarily to development of IFx-Hu2.0,manufacturing, clinical studies, and other early pre-clinical activitiesrelated to our portfolio. Research and development expenses are recognized as incurred, and payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received. Research and development expenses include:

| • |     | salaries, payroll taxes, employee benefits |

| • |     | external research and development expenses incurred under agreements with contract research organizations (“CROs”), and consultants to conduct our clinical studies; |

| • |     | laboratory supplies; |

| • |     | costs related to manufacturing product candidates, including fees paid to third-party manufacturers and raw material suppliers; |

| • |     | stock-based compensation charges for those individuals involved in research and development efforts; and |

| • |